At its annual meeting, VivoSim Labs stockholders approved a board authorization to execute a reverse stock split at any ratio between 1-for-5 and 1-for-20 by September 30, 2027. They also authorized the reduction of common stock purchase warrant exercise prices from $9.60 to $0.85 per share and approved the issuance of approximately 4.7 million shares upon their exercise. Additionally, shareholders ratified directors, auditors, executive compensation, and increased equity plan reserves by 3.165 million shares. VivoSim Labs operates in the medical simulation industry.
